University of Warmia and Mazury
13
0
1
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 13 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
INulin-type Fructans-induced Gut Microbiota Modulation Impact on GUT-SKIN Axis Parameters in Psoriasis
Role: collaborator
Effect of KETOgenic Diet on Metabolism, Inflammation, Nutrition Deficiencies and OXidative Stress in Women With Overweight
Role: collaborator
PFS and OS of Patients With Advanced Neuroendocrine Cancer (NEN) After Systemic Treatment
Role: lead
Ultrasonography in Fracture Management
Role: lead
Personalized CAPTEM Radiopeptide Therapy of Advanced, Non-resectable Neuroendocrine Cancer
Role: lead
Peptide Receptor Radionuclide Therapy in the Treatment of Advanced, Non-resectable and/or Symptomatic Tumors With SSTR Overexpression
Role: lead
Is Thoracic Paravertebral Block a Better Option Than Conscious Sedation for PRFA of Liver Tumors
Role: lead
Pupillometry - Future of Objective Pain Reaction Measurement While Unconscious
Role: lead
Prebiotic as a Supplement of Gluten-free Diet in the Management of Celiac Disease in Children
Role: collaborator
Therapeutic Effect of the Low FODMAP Diet in Children With Functional Abdominal Pain.
Role: lead
Arterial Hypertension in Men in the Warmia and Masuria Region
Role: lead
Autologous Bone Marrow Mesenchymal Stem Cells in the Treatment of Patients With Amyotrophic Lateral Sclerosis
Role: lead
Therapeutic Treatment of Amyotrophic Lateral Sclerosis
Role: lead
All 13 trials loaded